^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Erbitux (cetuximab)

    i
    Other names: C 225, IMC-C225, LY2939777, C225-03, ch225, C225, IMC C225, LY-2939777, IMCC225, LY 2939777, C-225
    Company:
    BMS, EMD Serono, Eli Lilly
    Drug class:
    EGFR inhibitor
    Related drugs:
    5d
    TORERO: Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=45, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • temsirolimus
    7d
    DARTBOARD: A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (clinicaltrials.gov)
    P2, N=50, Completed, University of Texas Southwestern Medical Center | Trial completion date: Sep 2024 --> Mar 2026
    Trial completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel
    7d
    Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer (clinicaltrials.gov)
    P=N/A, N=57, Completed, Centre Oscar Lambret | Unknown status --> Completed
    Trial completion
    |
    Erbitux (cetuximab)
    8d
    ALAFOSS-01: A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (clinicaltrials.gov)
    P1, N=17, Terminated, AstraZeneca | Phase classification: P1/2 --> P1
    Phase classification • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Erbitux (cetuximab)
    9d
    FID-007-003: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Fulgent Pharma LLC. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Erbitux (cetuximab) • paclitaxel • nanoencapsulated paclitaxel (FID-007)
    9d
    JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=48, Active, not recruiting, Allist Pharmaceuticals, Inc. | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Airuikai (glecirasib)
    9d
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Recruiting, Merck Sharp & Dohme LLC | N=57 --> 190
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    9d
    A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Multitude Therapeutics Inc.
    New P2 trial
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    13d
    Progression patterns and clinical outcomes in patients with cutaneous squamous-cell carcinoma following anti-PD-1 therapy failure. (PubMed, ESMO Open)
    In this cohort of patients with CSCC, distant metastatic and locoregional progression were the predominant patterns following anti-PD-1 failure, with lower TMB linked to primary resistance. Prior chemotherapy was associated with poorer OS. Select patients benefited from subsequent treatments, including cetuximab and local therapy.
    Clinical data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • EFS (Embryonal Fyn-Associated Substrate)
    |
    TMB-L
    |
    Erbitux (cetuximab) • Libtayo (cemiplimab-rwlc)
    13d
    KontRASt-R: Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    Erbitux (cetuximab) • Mekinist (trametinib) • Tevimbra (tislelizumab-jsgr) • batoprotafib (TNO155) • opnurasib (JDQ443)
    14d
    Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model. (PubMed, Clin Pharmacokinet)
    This model successfully described the PK of encorafenib over time and across tumor types. No dose modifications are suggested on the basis of intrinsic or extrinsic factors evaluated.
    PK/PD data • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    14d
    Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=55, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Kolupin (tunlametinib) • Dupert (fulzerasib)